Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Naruto TairaKosuke KashiwabaraJunji TsurutaniMasahiro KitadaMasato TakahashiHiroaki KatoYuichiro KikawaEiko SakataYoichi NaitoYoshie HasegawaTsuyoshi SaitoTsutomu IwasaTsutomu TakashimaTomohiko AiharaHirofumi MukaiFumikata Hara

Published in: Breast cancer (Tokyo, Japan) (2021)

The protocol was registered at the website of the University Hospital Medical Information Network (UMIN), Japan (protocol ID: UMIN000015516), on 01/11/2014. Details are available at the following address: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017916.

Keyphrases

phase ii study
metastatic breast cancer
randomized controlled trial
open label
locally advanced
healthcare
placebo controlled
minimally invasive
clinical trial
squamous cell carcinoma
health information
double blind